Enliven Therapeutics Completes Successful Public Offering of Stock and Warrants

Enliven Therapeutics Successfully Closes Public Offering

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company located in Boulder, Colorado, has recently announced the successful closure of its underwritten public offering. The offering included an impressive total of 9,920,987 shares of its common stock, along with a full exercise of the underwriters' option to acquire an additional 1,526,250 shares. This marks a significant moment for Enliven, especially given the public offering price set at $19.66 per share.

The public offering was designed not only to expand the company’s equity base but also to fuel its ongoing research and development projects focused on small molecule therapeutics. Enliven aims to tackle pressing issues in the field of oncology, striving to provide solutions that enhance both longevity and the quality of life for patients. Alongside common stock, Enliven offered pre-funded warrants, allowing certain investors the opportunity to purchase an additional 1,780,263 shares at a nearly equivalent price of $19.659 per pre-funded warrant.

This strategic move is expected to generate approximately $230 million in gross proceeds, a significant influx of funding crucial for driving forward Enliven’s innovative therapeutic approaches. Notably, the company intends to use these funds to enhance its capacity to address unmet medical needs, further emphasizing its commitment not only to develop new drugs but also to improve patient outcomes and overall well-being.

Leading the offering were notable underwriters, including Jefferies, Goldman Sachs & Co. LLC, TD Cowen, and Mizuho. These firms played integral roles as joint book-running managers, facilitating the successful navigation of this financial endeavor. Furthermore, LifeSci Capital served as the lead manager, contributing their expertise to ensure the offering’s success.

The offering fell under a Registration Statement filed with the SEC, which had previously been declared effective. This offers a degree of transparency and regulatory compliance that is crucial in the financial markets. Investors can access more information and the related documentation through the SEC's website, or they may contact the underwriters directly for copies of the final prospectus supplement.

Enliven Therapeutics highlights that this press release does not serve as an offer to sell or a solicitation for the purchase of any securities in states where such transactions would be deemed illegal without appropriate registration.

About Enliven Therapeutics

Founded with a mission to innovate and improve therapeutic practices, Enliven Therapeutics focuses on the discovery and development of small molecule drugs, monitoring both existing and emerging unmet medical needs. By employing a precision oncology approach, Enliven strives to enhance survival rates while ensuring improvements in the lives of patients battling cancer. Based in Boulder, Colorado, the company prides itself on leveraging clinically validated biological targets in its pursuit of innovative medical solutions.

As the biopharmaceutical industry continues to evolve, Enliven remains committed to pushing boundaries and redefining therapeutic success, ensuring that its developments have a lasting impact on healthcare.